INNsight Newsletter - August Edition
Welcome to the August edition of INNsight Newsletter, where we share with you the latest news and insights from?IQVIA Global Market Insights.?
This month's thought leadership includes:
Alzheimer’s Disease: A burgeoning Market on the Horizon
The World Health Organization has estimated that Alzheimer’s and other dementias affect more than 55 million people worldwide and impose a global annual economic burden of USD 1.3 trillion in associated healthcare costs. In this article, discover the latest breakthroughs in Alzheimer’s therapy. From Biogen’s discontinued aducanumab to Lilly’s approved donanemab, explore next-gen treatments and the R&D challenges to innovation. Click to learn more about the future of Alzheimer’s care.?Read more
Oral Obesity Therapies: Holding the Key to the Future
The treatment of obesity has been transformed by highly effective, injectable incretin-based pharmacotherapies. They have unleashed unprecedented consumer-led demand which continues to dramatically outstrip product supply, while the buzz surrounding novel weight loss treatments has firmly established those brands as household names. Despite the runaway commercial success of injectables semaglutide and tirzepatide, a number of important issues must be addressed for anti-obesity medicines to fulfil their tremendous potential as public health interventions. Read more
Rare Disease in APAC:??An Overview of the Market Landscape
In the APAC region, rare disease area is gaining momentum owing to the pronounced disease burden and unique challenges that patients face. In our two-part whitepaper series, we are discussing an overview of the rare disease landscape in the Asia-Pacific (APAC) region, covering the burden of disease, level of maturity, market size, challenges in rare disease management, and their potential solutions and innovations.?Read more
To learn about IQVIA Global Market Insights' solutions and how we can support your business, follow this link.